Detalhe da pesquisa
1.
Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab.
Clin Exp Dermatol
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38240024
2.
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
J Allergy Clin Immunol
; 144(3): 750-763, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31129129